Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Investigational

28

Possibly Marketed Outside US

5

Other

2

US Previously Marketed

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

32

1998

1

2015

1

2017

1

2023

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Isis Pharmaceuticals

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Nucleic Acid

25

Structurally Diverse

6

Concept

3

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

36

NCI_THESAURUS

36

CAS

31

ChEMBL

25

USAN

23

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTINEOPLASTIC AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER ANTINEOPLASTIC AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other antineoplastic agents

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

23

Salts, Hydrates, Esters, etc.

13

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "Pharmacologic Substance[C1909]|Biological Agent[C307]|Gene Therapy Agent" in comments (approximate match)

Showing 21 - 30 of 36 results

First page
Previous page
3
Next page
Next page

VALOCTOCOGENE ROXAPARVOVEC

681K1JDI8M

Status:

Possibly Marketed Outside US

First approved in 2023

Class:

STRUCTURALLY DIVERSE

VORETIGENE NEPARVOVEC

2SPI046IKD

Status:

Possibly Marketed Outside US

First approved in 2017

Class:

STRUCTURALLY DIVERSE

AEG-35156

T4V3YL9QHU

Status:

Other

Class:

CONCEPT

IMETELSTAT SODIUM

2AW48LAZ4I

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (MIXED)

ATESIDORSEN SODIUM

F3H59ON671

Export Data
Sequence Search

Status:

Investigational

Class:

NUCLEIC ACID

VOLANESORSEN SODIUM

6JON30SLDT

Export Data
Sequence Search

Status:

Investigational

Class:

NUCLEIC ACID

CUSTIRSEN SODIUM

ILE26V76EB

Export Data
Sequence Search

Status:

Investigational

Class:

NUCLEIC ACID

ALICAFORSEN SODIUM

4TWN6SZB8W

Export Data
Sequence Search

Status:

Investigational

Class:

NUCLEIC ACID

Alicaforsen is an antisense oligonucleotide targeted to down regulate the production of ICAM-1, a cell surface receptor which is involved in the process of inflammation. Alicaforsen selectively inhibits ICAM‑1 gene expression. Over-expression of ICAM...

‑1 occurs in a wide variety of inflammatory disorders, including ulcerative colitis (UC), pouchitis and tissues in the eye, gastrointestinal teact, lungs and skin. Alicaforsen is currently in development for the treatment of IBD. An enema formulation is currently in a pivotal Phase 3 study agreed with U.S., Canadian and European regulatory agencies in patients with active pouchitis. The study has completed enrollment of patients to approximately 40 trial centres across the U.S., Canada, Europe, and Israel, and is expected to report preliminary data in H1 2019. Under a rolling submission agreement with the FDA, Atlantic Healthcare has filed the nonclinical data package of its New Drug Application (NDA) for alicaforsen to treat pouchitis with the regulator. Alicaforsen has also been granted FDA Fast-Track designation, plus U.S. and European Orphan Drug designations for this indication.

APATORSEN SODIUM

3N4G7RE66Y

Export Data
Sequence Search

Status:

Investigational

Class:

NUCLEIC ACID

TRECOVIRSEN SODIUM

IZS5WP04OR

Export Data
Sequence Search

Status:

Investigational

Class:

NUCLEIC ACID

Showing 21 - 30 of 36 results

First page
Previous page
3
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1